期刊文献+

抗凝疗法及氮芥对肾病综合征患者尿量及纤维蛋白原的影响 被引量:3

The Influence of Urine Volume and Fibrinogen in Nephrotic Syndrome Therapy with Anticoagulant Therapy and Nitrogen Mustard
下载PDF
导出
摘要 目的 :探讨抗凝药物及氮芥对肾病综合征患者尿量及纤维蛋白原的影响。方法 :记录治疗前后患者的尿量及纤维蛋白原的改变 ,对治疗前后有显著差异者进行比较。结果 :尿激酶合氮芥 ,低分子肝素及肝素治疗前后尿量改变明显 (P <0 .0 5 ) ,尿激酶、肝素及低分子肝素可明显降低血浆纤维蛋白原含量 (P <0 .0 5 )。结论 :氮芥合尿激酶 ,肝素与低分子肝素对肾病综合征患者在利尿及降纤治疗上有优势。 Objective:To evaluate the influence of anticoagulant therapy and Nitrogen mustard.on urine volume and fibrinogen in patients with nephrotic syndrome.Methods:Changes of urine volume and fibrinogen after the treatment were recorded, and these changes were compared. Results:After the treatment with urokinase plus nitrogen mustard and heparin,the volume of urime obviously increased(P<0.05).These drugs can remarkably lower the conteut of plaswa fibrinogen(P<0.01). Conclusions:The therapeutic methods of combined usage of urokinase with nitrogen mustard,Heparin and Low molecular heparin are superior in promoting diuresis and in lowering the fibrinogen in nephrotic syndrome patients.
出处 《中国中西医结合肾病杂志》 2002年第6期334-335,338,共3页 Chinese Journal of Integrated Traditional and Western Nephrology
关键词 抗凝疗法 氮芥 肾病综合征 治疗 尿量 纤维蛋白原 Nephrotic syndrome Therapy Urine volume Fibrinogen
  • 相关文献

参考文献6

二级参考文献13

  • 1[1]Suzuki T,Otak S,Naganuma S,et al. Clinical applications of fragmin (FR-860) in hemodialysis :multi center cooperative study in Japan. Seminals Thrombosis Hemostasis,1990;16 (suppl) : 46
  • 2[2]Anastassiades E, Ireland H, Flynn A, et al. A lowmolecular-weight heparin (kabi 2165,Fragmin) in repeated use for hemodialysis: prevention of clotting and prolongation of the venous conpression time in comparison with commercial unfractionated heparin.Dial Transplant, 1990 ; 5 : 135
  • 3[3]Shuichiro I,Masahiko N,Hidetade K. Study of anti coagulating mechansm of low molecular weight heparin.Thrombosis Research, 1992 ; 65 : 801
  • 4[4]Hirsh T,Levine MN. Low molecular weight heparin.Blood,1992;79 : 1
  • 5[5]Gran E,Siguenza F,Maduell F,et al. Low molecular weight heparin (CY-216)cersus unfraction heparin in chronic hemodiaysis. Nephron, 1992; 62: 13
  • 6[6]Wei SS, Ellis PW,Moetal M, et al. Effect of heparin modeling on delivered hemodialysis therapy. Am J Kid Dis,1994;23 : 389
  • 7[7]Shaldon S,Koch KM. Survival and adequacy in longterm hemodialysis, Nephron, 1991 ; 59 : 353
  • 8[8]Moia M,Graziani G. Rationale for the use of a lowmolecular weight heparin during hemodialysis with polysuphone membrane in uremic patients. Annals Italian MedicineInternational, 1997; 12(2) : 67
  • 9[9]Hall AV, Clark WF, Parbtani A. Heparin-induced thrombocytopenia. Clinical Nephrology, 1992 ; 30: 86
  • 10[10]Versttaete M. Pharmacotherapeutic aspects of unfraction-ated and low molecular weight heparin.Drugs,1990;40: 498

共引文献27

同被引文献15

引证文献3

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部